Two nominees for high-profile health roles in the Trump administration faced scrutiny from the Senate health committee Wednesday—and both crashed and burned in their own special ways.

The Senate Committee on Health, Education, Labor, and Pensions (HELP) scrutinized Erica Schwartz, the nominee for director of the Centers for Disease Control and Prevention, and Sean Kaufman, up for the role of assistant secretary for preparedness and response.

Schwartz's assignment

Public health experts were "cautiously optimistic" about Schwartz's nomination. She is well-respected and holds views in line with evidence-based medicine, including being supportive of vaccinations—in contrast to anti-vaccine Health Secretary Robert F. Kennedy Jr., whom she will serve under. She is also highly qualified for the role, with a medical degree, a master's degree in public health, and a law degree. She's had a long career as a Navy Officer and previously held the roles of chief medical officer for the US Coast Guard and deputy surgeon general in the first Trump administration.

Read full article

Comments

Independent advisors for the Food and Drug Administration on Friday voted 9–0 in support of approving Moderna's seasonal mRNA flu vaccine, which a Trump appointee at the agency initially tried to block from even being reviewed.

In an all-day meeting, members of the FDA's advisory committee—known as VRBPAC for Vaccines and Related Biological Products Advisory Committee—pored over data and presentations on the vaccine, which is dubbed mRNA-1010 and branded as mFlusiva. The presentations included a review from FDA scientists, which was supportive of the vaccine.

Data from a Phase 3 trial including over 40,000 adults age 50 and older found the mRNA vaccine was around 27 percent more effective against seasonal flu than a standard flu shot. A smaller Phase 3 trial, involving data from nearly 3,000 people age 65 years and older, showed the shot produces stronger immune responses than a high-dose flu vaccine, which is recommended for this age group. The safety profile of the vaccine was also generally good.

Read full article

Comments